Current Report Filing (8-k)
October 01 2020 - 4:07PM
Edgar (US Regulatory)
false 0001711279 0001711279 2020-10-01 2020-10-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 1, 2020
KRYSTAL BIOTECH, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38210
|
|
82-1080209
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
|
2100 Wharton Street, Suite 701
Pittsburgh, Pennsylvania 15203
|
(Address of principal executive offices, including Zip Code)
|
Registrant’s telephone number, including area code: (412) 586-5830
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock
|
|
KRYS
|
|
Nasdaq
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On October 1, 2020, representatives of Krystal Biotech, Inc., a Delaware corporation (the “Company”), made a presentation to the 2020 Virtual debra Care Conference, which included an update on the Company’s GEM-3 clinical trials for beremagene geperpavec (“B-VEC”). A copy of the Company’s presentation is attached as Exhibit 99.1 hereto and incorporated by reference herein.
In accordance with General Instruction B.2 to Form 8-K, the information contained in this Current Report, including Exhibit 99.1 attached hereto, is being “furnished” and not “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under such section. Furthermore, such information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: October 1, 2020
|
|
|
|
KRYSTAL BIOTECH, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Krish S. Krishnan
|
|
|
|
|
Name:
|
|
Krish S. Krishnan
|
|
|
|
|
Title:
|
|
President and Chief Executive Officer
|
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Oct 2023 to Oct 2024